Soo Aleman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7401504/publications.pdf

Version: 2024-02-01

78 papers	8,108 citations	218677 26 h-index	74163 75 g-index
83 all docs	83 docs citations	83 times ranked	14215 citing authors

#	Article	IF	Citations
1	COVIDâ€19â€specific metabolic imprint yields insights into multiorgan system perturbations. European Journal of Immunology, 2022, 52, 503-510.	2.9	7
2	Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nature Medicine, 2022, 28, 472-476.	30.7	333
3	T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. Haematologica, 2022, 107, 1000-1003.	3.5	14
4	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med, 2022, 3, 137-153.e3.	4.4	19
5	High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV â€“ but HIV viremia matters?. Aids, 2022, 36, 479-481.	2.2	24
6	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. Molecular Medicine, 2022, 28, 20.	4.4	18
7	Probabilistic classification of antiâ€SARSâ€CoVâ€2 antibody responses improves seroprevalence estimates. Clinical and Translational Immunology, 2022, 11, e1379.	3.8	4
8	Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2022, 42, 716-727.	3.8	13
9	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	4.9	10
10	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	8.1	237
11	Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. Journal of Clinical Immunology, 2022, 42, 1130-1136.	3.8	13
12	Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study. Hepatology Communications, 2022, 6, 2418-2430.	4.3	12
13	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine. Molecular Medicine, 2022, 28, 54.	4.4	18
14	The Karolinska <scp>KI</scp>/K <scp>COVID</scp>â€19 immune atlas: An open resource for immunological research and educational purposes. Scandinavian Journal of Immunology, 2022, 96, .	2.7	4
15	REPLY:. Hepatology, 2021, 74, 1127-1128.	7.3	0
16	SARSâ€CoVâ€2â€specific humoral and cellular immunity persists through 9 months irrespective of COVIDâ€19 severity at hospitalisation. Clinical and Translational Immunology, 2021, 10, e1306.	3.8	36
17	Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection. JCI Insight, 2021, 6, .	5.0	29
18	Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101564.	1.5	11

#	Article	IF	Citations
19	Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with directâ€acting antivirals. GastroHep, 2021, 3, 185-195.	0.6	3
20	Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. Journal of Infectious Diseases, 2021, 224, 407-414.	4.0	43
21	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVIDâ€19. Liver International, 2021, 41, 2024-2031.	3.9	9
22	Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. PLoS ONE, 2021, 16, e0253710.	2.5	3
23	Risk of hepatocellular carcinoma in hepatitis B and D virus coâ€infected patients: A systematic review and metaâ€analysis of longitudinal studies. Journal of Viral Hepatitis, 2021, 28, 1431-1442.	2.0	20
24	Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Reports, 2021, 3, 100318.	4.9	5
25	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	52
26	Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	104
27	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine, 2021, 74, 103705.	6.1	161
28	Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases, 2020, 52, 1-22.	2.8	23
29	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 2020, 183, 158-168.e14.	28.9	1,561
30	Natural killer cell immunotypes related to COVID-19 disease severity. Science Immunology, 2020, 5, .	11.9	344
31	Innate lymphoid cell composition associates with COVIDâ€19 disease severity. Clinical and Translational Immunology, 2020, 9, e1224.	3.8	56
32	High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. Scandinavian Journal of Gastroenterology, 2020, 55, 574-580.	1.5	1
33	Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 63-70.	2.5	7
34	Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. New England Journal of Medicine, 2020, 382, 1018-1028.	27.0	208
35	Longâ€Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liverâ€Related Outcomes. Hepatology, 2020, 72, 1177-1190.	7.3	65
36	Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. Cells, 2020, 9, 1471.	4.1	6

#	Article	IF	Citations
37	Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. Scientific Reports, 2020, 10, 2081.	3.3	9
38	Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2020, 55, 178-183.	1.5	12
39	Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus. Gut, 2020, 69, 2203-2213.	12.1	3
40	Frequent loss to followâ€up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver International, 2020, 40, 1832-1840.	3.9	31
41	MAIT cell activation and dynamics associated with COVID-19 disease severity. Science Immunology, 2020, 5, .	11.9	147
42	Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scandinavian Journal of Gastroenterology, 2019, 54, 1042-1050.	1.5	10
43	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	5.8	52
44	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Annals of Internal Medicine, 2019, 171, 318.	3.9	95
45	Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infectious Diseases, 2019, 19, 955.	2.9	15
46	Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. European Journal of Gastroenterology and Hepatology, 2019, 31, 506-513.	1.6	16
47	Tissueâ€resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce ILâ€17. European Journal of Immunology, 2019, 49, 133-143.	2.9	85
48	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infectious Diseases, 2018, 50, 569-583.	2.8	20
49	IL13RÎ±2 expression identifies tissueâ€resident ILâ€22â€producing PLZF⁺ innate TÂcells in the human liver. European Journal of Immunology, 2018, 48, 1329-1335.	2.9	13
50	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
51	Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS ONE, 2018, 13, e0190146.	2.5	9
52	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
53	Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties. Journal of Virology, 2017, 91, .	3.4	13
54	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 325-336.	8.1	208

#	Article	IF	Citations
55	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infectious Diseases, 2017, 49, 561-575.	2.8	14
56	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. Journal of Hepatology, 2017, 66, 485-493.	3.7	225
57	Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scandinavian Journal of Gastroenterology, 2017, 52, 61-68.	1.5	12
58	The hurdle with remaining risk for hepatocellular carcinoma in cirrhotic patients after a hepatitis C cure. Hepatology, Medicine and Policy, 2016, 1, 11.	1.7	0
59	Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. Clinical Infectious Diseases, 2016, 63, 723-729.	5.8	41
60	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infectious Diseases, 2016, 48, 251-261.	2.8	12
61	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scandinavian Journal of Gastroenterology, 2015, 50, 233-244.	1.5	33
62	Functional Attributes of Responding T Cells in HCV Infection: The Recent Advances in Engineering Functional Antiviral T Cells. Archivum Immunologiae Et Therapiae Experimentalis, 2014, 62, 23-30.	2.3	4
63	Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients. Biochemical and Biophysical Research Communications, 2013, 433, 31-35.	2.1	5
64	A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis Câ€“Associated Liver Cirrhosis. Clinical Infectious Diseases, 2013, 57, 230-236.	5.8	206
65	Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-Î³ production. Gut, 2012, 61, 589-596.	12.1	13
66	TCR-Redirected Human T Cells Inhibit Hepatitis C Virus Replication: Hepatotoxic Potential Is Linked to Antigen Specificity and Functional Avidity. Journal of Immunology, 2012, 189, 4510-4519.	0.8	24
67	Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. Scandinavian Journal of Infectious Diseases, 2012, 44, 502-521.	1.5	13
68	Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population. Scandinavian Journal of Gastroenterology, 2011, 46, 1118-1126.	1.5	12
69	Hepatocellular carcinoma in individuals with HBV infection or HBVâ€“HCV co-infection in a low endemic country. Scandinavian Journal of Gastroenterology, 2010, 45, 944-952.	1.5	10
70	Hepatitis C infection among injection drug users in Stockholm Sweden: Prevalence and gender. Scandinavian Journal of Infectious Diseases, 2009, 41, 679-684.	1.5	28
71	Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide communityâ€based register study. Journal of Viral Hepatitis, 2008, 15, 538-550.	2.0	67
72	Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scandinavian Journal of Gastroenterology, 2008, 43, 1378-1386.	1.5	18

#	Article	IF	Citations
73	Minor nef gene alterations after human HIV-DNA immunisation. Aids, 2004, 18, 817-819.	2.2	2
74	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. Aids, 2002, 16, 1039-1044.	2.2	99
75	High Plasma Levels of Soluble Fas in HIV Type 1-Infected Subjects Are Not Normalized during Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2000, 16, 1379-1384.	1.1	18
76	Long-Term Effects of Antiretroviral Combination Therapy on HIV Type 1 DNA Levels. AIDS Research and Human Retroviruses, 1999, 15, 1249-1254.	1.1	17
77	Kinetics of Î²-Chemokine Levels during Anti-HIV Therapy. Antiviral Therapy, 1999, 4, 109-115.	1.0	6
78	Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron. Nature Medicine, 0, , .	30.7	14